280 related articles for article (PubMed ID: 26298202)
1. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes.
Ryk C; Koskela LR; Thiel T; Wiklund NP; Steineck G; Schumacher MC; de Verdier PJ
Redox Biol; 2015 Dec; 6():272-277. PubMed ID: 26298202
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
3. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
5. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases.
Amasyali AS; Kucukgergin C; Erdem S; Sanli O; Seckin S; Nane I
J Urol; 2012 Dec; 188(6):2398-403. PubMed ID: 23088972
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary-bladder cancer.
Ryk C; Wiklund NP; Nyberg T; de Verdier PJ
Nitric Oxide; 2011 Oct; 25(3):338-43. PubMed ID: 21703358
[TBL] [Abstract][Full Text] [Related]
9. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
10. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
[TBL] [Abstract][Full Text] [Related]
11. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
[TBL] [Abstract][Full Text] [Related]
13. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
[TBL] [Abstract][Full Text] [Related]
14. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
15. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
17. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
[TBL] [Abstract][Full Text] [Related]
18. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
[TBL] [Abstract][Full Text] [Related]
20. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population.
Gangwar R; Mandhani A; Mittal RD
Ann Surg Oncol; 2009 Jul; 16(7):2028-34. PubMed ID: 19412632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
